



May 14, 1984

National Institutes of Health  
Bethesda, Maryland 20205  
Building : 5  
Room : B1-25  
(301) 496- 4012

Dr. Robert C. Gallo  
Chief, Laboratory of  
Tumor Cell Biology  
National Cancer Institute  
National Institutes of Health  
Building 37, Room 6A-09  
Bethesda, MD 20205

Dear ~~Dr. Gallo~~:

Dr. Janet Hartley and I have been asked to assist Dr. Kenneth Sell in the isolation of HTLV III-type retroviruses from patients with AIDS. Your recent paper in Science (vol. 224, pp. 497-500) describes the HT line for the efficient propagation of lymphotropic retroviruses derived from AIDS patients. I would appreciate obtaining this cell line to facilitate our research efforts. We would, of course, not distribute the line to other investigators without your permission.

Sincerely,

Malcolm A. Martin, M.D.  
Chief, Laboratory of Molecular  
Microbiology  
National Institute of Allergy  
and Infectious Diseases

cc:  
Dr. Janet Hartley  
Dr. Kenneth Sell



National Institutes of Health  
National Cancer Institute  
Bethesda, Maryland 20205

Building 37, Room 6A05  
(301) 496-6007

June 22, 1984

Malcolm A. Martin, M.D.  
Chief, Laboratory of  
Molecular Microbiology  
NIAID  
Building 5, Room B1-25

Dear Mal,

I am sorry for the delay in response to your letter of May 14 which I first saw this month because of the Uppsala, Helsinki and Stockholm meetings -- which you may be aware of. After that I had a few commitments here as you know.

I am pleased to send you HTLV-III producing cell lines if you want them but the uninfected HT lines are still being characterized for the first detailed publication on them. Therefore, they are not generally available now. They will be by the end of the summer.

Please let me know your wishes, and I would also appreciate it if you let me know what you plan to do with the uninfected cells. For instance, I do not think it would be appropriate for you to put the French isolate in them. That is for them to do in collaboration with me and my co-workers and is on-going. Perhaps we can do something in collaboration with you. In this regard, there is no one in the biology of retroviruses I respect more than Janet Hartley and would appreciate her involvement in joint NCI-NIAID studies.

Sincerely yours,

Robert C. Gallo, M.D.

RCG:tas

Attachment

cc: Dr. Janet Hartley  
Dr. Peter Fischinger  
Dr. Vincent DeVita  
Dr. James Wyngaarden

Agreement for Receiving H9 or H9/HTLV-III<sub>B</sub> Cell Line

I have read and agree to adhere to the following guidelines for use of H9/HTLV-III<sub>B</sub>:

1. Use of H9 or H9/HTLV-III<sub>B</sub> will be limited to my immediate laboratory. I will not give it out without prior written approval from Dr. Gallo.
2. Work performed will be on a collaborative basis with Dr. Gallo and his laboratory unless stated otherwise.
3. H9 or H9/HTLV-III<sub>B</sub> will not be used for commercial purposes. A U.S. Government (National Cancer Institute) patent is in effect.
4. Use of the H9/HTLV-III<sub>B</sub> line or virus produced from it will be according to U.S. Government recommendations (see attached). Work can be carried out in a biosafety level 2 facility if the equipment, techniques and access to the work area are maintained as biosafety level 3. Large scale production of the virus requires strict biosafety level 3 containment.
5. Any operations using the infected cell outside of biocontainment will be after treatment such as gluteraldehyde fixation.
6. Work with these reagents will not be published without prior approval by Dr. Gallo.
7. Reagents will not be used in comparisons with other viruses.

Signature \_\_\_\_\_ Date \_\_\_\_\_

Malcolm A. Martin, M.D.  
Chief, Laboratory of  
Molecular Microbiology  
National Institute of Allergy and  
Infectious Diseases  
Building 5, Room B1-25  
Bethesda, Maryland 20205